|
Myocardial perfusion PET imaging to evaluate coronary microvascular dysfunction in men with prostate cancer receiving androgen deprivation therapy. |
| |
|
Consulting or Advisory Role - AstraZeneca; Janssen Oncology; Merck; Modra Pharmaceuticals; Myovant Sciences; Pfizer/EMD Serono; Regeneron |
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Merck (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Merck |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Calithera Biosciences; Eisai; Exelixis; Merck Sharp & Dohme; Pfizer |
Expert Testimony - Lilly (I) |
| |
|
Stock and Other Ownership Interests - Bluebird Bio (I); Gilead Sciences (I); Johnson & Johnson (I); Merck (I); Novartis (I); Pfizer (I); Pfizer (I); Portola Pharmaceuticals (I) |
Consulting or Advisory Role - Boehringer Ingelheim (I); Health Advances; Novartis (I); Novocure (I) |
Research Funding - AstraZeneca (I); Lilly (I); Pfizer; Trizell (I) |
| |
|
Stock and Other Ownership Interests - GNS Healthcare; Google; Merck |
Consulting or Advisory Role - Cancer Study Group; GNS Healthcare |
Travel, Accommodations, Expenses - Conquer Cancer Foundation; Flatiron Health |
| |
|
Consulting or Advisory Role - Merck Sharp & Dohme |
Research Funding - Astellas Pharma; Merck Sharp & Dohme; Roche/Genentech |
| |
|
No Relationships to Disclose |
| |
|
Stock and Other Ownership Interests - ImaginAb; Reflexion Medical; Trevarx Biomedical (I) |
Consulting or Advisory Role - Philips Healthcare |
Other Relationship - ImaginAb; Reflexion Medical |
| |
|
|
Consulting or Advisory Role - American College of Cardiology; Bioinvent; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Gilead Sciences; Mateon Therapeutics; Roche; Roche |
Speakers' Bureau - Bristol-Myers Squibb |
Research Funding - Pfizer; Roche; Singulex |
Patents, Royalties, Other Intellectual Property - Have a patent on the use of neuregulin-1b as a biomarker in heart failure; Pending patent application on the use of IgE as a biomarker of cardiotoxicity |